SecBot SecBot
8-K ·Filed Feb 25, 2026

MIRM

Mirum Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001759425-26-000010
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The significant revenue growth and raised guidance suggest strong commercial momentum. The upcoming clinical catalysts, particularly the Q2 2026 topline data for volixibat in PSC, could be major value drivers. The increased cash position provides runway for pipeline advancement.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.19
T+0 close · Feb 25, 2026 · via day close
Latest settled
+6.97%
T+60 · $98.62
Vs SPY
−1.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $92.19entry
  2. T+1 · 9mo ago +0.11%α +0.59% · $92.29
  3. T+5 · 9mo ago −4.72%α −3.56% · $87.84
  4. T+20 · 8mo ago −3.59%α +2.82% · $88.88
  5. T+60 · 6mo ago +6.97%α −1.20% · $98.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals reported strong 2025 financial results with $521.3 million in net product sales, representing 55% year-over-year growth. The company raised its 2026 guidance to $630-$650 million in global net product sales and highlighted four upcoming clinical catalysts, including topline data for volixibat in PSC expected in Q2 2026.

Key Financial Metrics

Revenue
$521.3M
+55.0% YoY
EPS
$-0.47
Guidance
$630M-$650M
raised

Key Facts

  • 2025 net product sales of $521.3 million, up 55% YoY from $336.4 million in 2024
  • 2026 guidance raised to $630-$650 million in global net product sales
  • LIVMARLI net sales reached $360.0 million in 2025, up 69% YoY
  • Bile Acid Medicines net sales reached $161.3 million in 2025, up 31% YoY
  • Unrestricted cash, cash equivalents and investments increased to $391.4 million as of December 31, 2025
  • Four potentially registrational readouts expected over the next 18 months, starting with volixibat VISTAS study in PSC in Q2 2026

Financial Impact

2025 revenue of $521.3 million (55% YoY growth) with 2026 guidance of $630-$650 million

revenueguidancecash

Segment Breakdown

SegmentRevenueGrowth
LIVMARLI$360.0M+69.0%
Bile Acid Medicines$161.3M+31.0%

Risk Factors

  • Increased operating expenses from $424.5 million in 2024 to $543.4 million in 2025
  • Continued net losses, though improving from $87.9 million in 2024 to $23.4 million in 2025

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759425-26-000010
Document: mirm-20260225.htm0001759425-26-000010
Document: 0001759425-26-000010-index-headers.html0001759425-26-000010
Document: 0001759425-26-000010-index.html0001759425-26-000010
Document: 0001759425-26-000010.txt0001759425-26-000010

US Market Status

Market Closed · Opens in 8h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026